{"protocolSection":{"identificationModule":{"nctId":"NCT02264990","orgStudyIdInfo":{"id":"M14-359"},"secondaryIdInfos":[{"id":"2014-002565-30","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"AbbVie","class":"INDUSTRY"},"briefTitle":"Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers","officialTitle":"A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers"},"statusModule":{"statusVerifiedDate":"2021-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-09-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-11-14","type":"ACTUAL"},"completionDateStruct":{"date":"2020-02-21","type":"ACTUAL"},"studyFirstSubmitDate":"2014-10-09","studyFirstSubmitQcDate":"2014-10-09","studyFirstPostDateStruct":{"date":"2014-10-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-02-08","resultsFirstSubmitQcDate":"2021-02-08","resultsFirstPostDateStruct":{"date":"2021-02-26","type":"ACTUAL"},"dispFirstSubmitDate":"2020-10-26","dispFirstSubmitQcDate":"2020-10-26","dispFirstPostDateStruct":{"date":"2020-10-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-02-08","lastUpdatePostDateStruct":{"date":"2021-02-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AbbVie","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer."},"conditionsModule":{"conditions":["Non-squamous Non-small Cell Lung Cancer"],"keywords":["veliparib","carboplatin","paclitaxel","cisplatin","pemetrexed","Poly Adenosine diphosphate (ADP)-ribose Polymerase (PARP)","Metastatic","Non-squamous","Non-small cell lung cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":595,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Veliparib + Carboplatin + Paclitaxel","type":"EXPERIMENTAL","description":"Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an area under the curve (AUC) of 6 mg/mL\\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.","interventionNames":["Drug: Paclitaxel","Drug: Carboplatin","Drug: Veliparib","Drug: Pemetrexed"]},{"label":"Investigator's Choice Chemotherapy","type":"ACTIVE_COMPARATOR","description":"Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:\n\n* Carboplatin AUC 6 mg/mL\\*min + paclitaxel 200 mg/m²\n* Cisplatin 75 mg/m² + pemetrexed 500 mg/m²\n* Carboplatin AUC 6 or AUC 5 mg/mL\\*min + pemetrexed 500 mg/m²\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.","interventionNames":["Drug: Paclitaxel","Drug: Carboplatin","Drug: Cisplatin","Drug: Pemetrexed"]}],"interventions":[{"type":"DRUG","name":"Paclitaxel","description":"Administered by Intravenous infusion on Day 1 of each 21-day cycle","armGroupLabels":["Investigator's Choice Chemotherapy","Veliparib + Carboplatin + Paclitaxel"]},{"type":"DRUG","name":"Carboplatin","description":"Administered by Intravenous infusion on Day 1 of each 21-day cycle","armGroupLabels":["Investigator's Choice Chemotherapy","Veliparib + Carboplatin + Paclitaxel"]},{"type":"DRUG","name":"Cisplatin","description":"Administered by Intravenous infusion on Day 1 of each 21-day cycle","armGroupLabels":["Investigator's Choice Chemotherapy"]},{"type":"DRUG","name":"Veliparib","description":"Oral capsule, administered twice daily for 7 days in each 21-day cycle","armGroupLabels":["Veliparib + Carboplatin + Paclitaxel"],"otherNames":["ABT-888"]},{"type":"DRUG","name":"Pemetrexed","description":"Administered by Intravenous infusion on Day 1 of each 21-day cycle","armGroupLabels":["Investigator's Choice Chemotherapy","Veliparib + Carboplatin + Paclitaxel"],"otherNames":["Alimta"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival (OS) in the Lung Subtype Panel Positive Subgroup","description":"Overall survival is defined as the time from the date that the participant was randomized to the date of the participant's death. Overall survival was estimated using Kaplan-Meier methodology. Participants still alive at the data cut-off date were censored at the date they were last known to be alive.","timeFrame":"From randomization up to the data cut-off date of 15 July 2019; median follow-up time was 44.5 and 45.3 months in LSP+ participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively."}],"secondaryOutcomes":[{"measure":"Progression Free Survival (PFS) in the Lung Subtype Panel Positive Subgroup","description":"Progression-free survival is defined as the time from the date of randomization to the date of disease progression (PD) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death (all causes of mortality), whichever occurred first.\n\nPD: At least a 20% increase in the size of target lesions, taking as reference the smallest size recorded since the treatment started (Baseline or after) with an absolute increase of at least 5 mm, the appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.\n\nPFS was estimated using Kaplan-Meier methodology. Participants who did not have an event of disease progression or had not died on or before the cutoff date were censored at the date of their last disease progression assessment on or before the cut-off date. Any PD and death occurring \\> 26 weeks and \\> 12 weeks after the previous assessment, respectively, were excluded and patients were censored at last assessment before PD or death.","timeFrame":"From randomization up to the data cut-off date of 15 July 2019; the median follow-up time was 44.5 and 45.3 months in LSP+ participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively."},{"measure":"Objective Response Rate (ORR) in the Lung Subtype Panel Positive Subgroup","description":"Objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria. Response must have been confirmed at a consecutive assessment 28 days or more after the assessment at which response was first observed.\n\nCR: The disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters, persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, or any new lesions.","timeFrame":"Assessed on Day 1 of Cycles 3 and 5 then every 9 weeks for 1 year or until maintenance therapy was discontinued, then every 12 weeks until radiographic progression or death; median time on follow-up was 5.2 and 6.3 months in each group, respectively."},{"measure":"Overall Survival in All Participants","description":"Overall survival is defined as the time from the date that the participant was randomized to the date of the participant's death. OS was estimated using Kaplan-Meier methodology. Participants still alive at the data cut-off date were censored at the date they were last known to be alive.","timeFrame":"From randomization up to the data cut-off date of 15 July 2019; the median OS follow-up time was 45.4 and 44.6 months in all participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively."},{"measure":"Progression Free Survival (PFS) in All Participants","description":"Progression-free survival is defined as the time from the date of randomization to the date of disease progression (PD) per RECIST version 1.1 or death (all causes of mortality), whichever occurred first.\n\nPD: At least a 20% increase in the size of target lesions, taking as reference the smallest size recorded since the treatment started (Baseline or after) with an absolute increase of at least 5 mm, the appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.\n\nPFS was estimated using Kaplan-Meier methodology. Participants who did not have an event of disease progression or had not died on or before the cut-off date were censored at the date of their last disease progression assessment on or before the cut-off date. Any PD and death occurring \\> 26 weeks and \\> 12 weeks after the previous assessment, respectively, were excluded and patients were censored at last assessment before PD or death.","timeFrame":"From randomization up to the data cut-off date of 15 July 2019; the median follow-up time was 45.4 and 44.6 months in all participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively."},{"measure":"Objective Response Rate (ORR) in All Participants","description":"Objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per RECIST version 1.1 criteria. Response must have been confirmed at a consecutive assessment 28 days or more after the assessment at which response was first observed.\n\nCR: The disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters, persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, or any new lesions.","timeFrame":"Assessed on Day 1 of Cycles 3 and 5 then every 9 weeks for 1 year or until maintenance therapy was discontinued, then every 12 weeks until radiographic progression or death; median time on follow-up was 6.7 and 5.9 months in each group, respectively."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject must be ≥ 18 years of age with life expectancy \\> 12 weeks.\n* Subject must have cytologically or histologically confirmed advanced or metastatic non-squamous NSCLC and are current or former smokers.\n* Subject must have NSCLC that is not amenable to surgical resection or radiation with curative intent at time of screening.\n* Subject must have at least 1 unidimensional measurable NSCLC lesion on a computed tomography (CT) scan as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n\nExclusion Criteria:\n\n* Subject has a known hypersensitivity to paclitaxel or to other drugs formulated with polyethoxylated castor oil (Cremophor).\n* Subject has a known hypersensitivity to platinum compounds.\n* Subject has peripheral neuropathy ≥ grade 2.\n* Subject has squamous NSCLC, or an untreated known epidermal growth factor receptor (EGFR) mutation of exon 19 deletion or L858R mutation in exon 21, or a known anaplastic lymphoma kinase (ALK) gene rearrangement.\n* Subject has received prior cytotoxic chemotherapy or chemoradiotherapy for NSCLC.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"AbbVie Inc.","affiliation":"AbbVie","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Clearview Cancer Institute /ID# 131434","city":"Huntsville","state":"Alabama","zip":"35805","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"University of South Alabama /ID# 131518","city":"Mobile","state":"Alabama","zip":"36617","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"Highlands Oncology Group /ID# 131250","city":"Springdale","state":"Arkansas","zip":"72762","country":"United States","geoPoint":{"lat":36.18674,"lon":-94.12881}},{"facility":"CBCC Global Research, Inc. at /ID# 132709","city":"Bakersfield","state":"California","zip":"93309","country":"United States","geoPoint":{"lat":35.37329,"lon":-119.01871}},{"facility":"California Cancer Assoc. R&E /ID# 131392","city":"Encinitas","state":"California","zip":"92024","country":"United States","geoPoint":{"lat":33.03699,"lon":-117.29198}},{"facility":"California Cancer Assoc. R&E /ID# 131949","city":"Encinitas","state":"California","zip":"92024","country":"United States","geoPoint":{"lat":33.03699,"lon":-117.29198}},{"facility":"LA Hem-Oncology Med Group /ID# 131639","city":"Los Angeles","state":"California","zip":"90017","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"St Jude Hospital dba St Joseph /ID# 132943","city":"Santa Rosa","state":"California","zip":"95403","country":"United States","geoPoint":{"lat":38.44047,"lon":-122.71443}},{"facility":"Icri /Id# 132942","city":"Whittier","state":"California","zip":"90603","country":"United States","geoPoint":{"lat":33.97918,"lon":-118.03284}},{"facility":"University of Florida - Archer /ID# 132408","city":"Gainesville","state":"Florida","zip":"32610","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"NorthShore University HealthSystem - Evanston Hospital /ID# 130200","city":"Evanston","state":"Illinois","zip":"60201","country":"United States","geoPoint":{"lat":42.04114,"lon":-87.69006}},{"facility":"Goshen Center for Cancer Care /ID# 130216","city":"Goshen","state":"Indiana","zip":"46526","country":"United States","geoPoint":{"lat":41.58227,"lon":-85.83444}},{"facility":"University of Louisville /ID# 130217","city":"Louisville","state":"Kentucky","zip":"40202","country":"United States","geoPoint":{"lat":38.25424,"lon":-85.75941}},{"facility":"Cancer Center of Acadiana /ID# 133611","city":"Lafayette","state":"Louisiana","zip":"70503","country":"United States","geoPoint":{"lat":30.22409,"lon":-92.01984}},{"facility":"Henry Ford Health System /ID# 130234","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Herbert Herman Cancer Center /ID# 130239","city":"Lansing","state":"Michigan","zip":"48912","country":"United States","geoPoint":{"lat":42.73253,"lon":-84.55553}},{"facility":"Washington University-School of Medicine /ID# 131651","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"MD Anderson Cancer Center at Cooper - Camden /ID# 131490","city":"Camden","state":"New Jersey","zip":"08103","country":"United States","geoPoint":{"lat":39.92595,"lon":-75.11962}},{"facility":"Gabrail Cancer Center Research /ID# 130205","city":"Canton","state":"Ohio","zip":"44718","country":"United States","geoPoint":{"lat":40.79895,"lon":-81.37845}},{"facility":"Univ Oklahoma HSC /ID# 132888","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Albert Einstein Medical Center /ID# 134498","city":"Philadelphia","state":"Pennsylvania","zip":"19141","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Allegheny General Hospital /ID# 134049","city":"Pittsburgh","state":"Pennsylvania","zip":"15212","country":"United States","geoPoint":{"lat":40.44062,"lon":-79.99589}},{"facility":"The Jones Clinic, PC /ID# 130215","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"UT Southwestern Medical Center /ID# 130236","city":"Dallas","state":"Texas","zip":"75390-7208","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Univ Texas HSC San Antonio /ID# 132972","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Coiba /Id# 132153","city":"Berazategui, Buenos Aires","zip":"1884","country":"Argentina"},{"facility":"Centro Investigacion Pergamino /ID# 132152","city":"Pergamino","zip":"2700","country":"Argentina","geoPoint":{"lat":-33.89101,"lon":-60.57462}},{"facility":"Hospital Britanico /ID# 134874","city":"Rosario, Santa FE","zip":"2000","country":"Argentina"},{"facility":"Instituto de Oncologia de Rosa /ID# 132150","city":"Rosario, Santa FE","zip":"2000","country":"Argentina"},{"facility":"St George Hospital /ID# 132481","city":"Kogarah","state":"New South Wales","zip":"2217","country":"Australia","geoPoint":{"lat":-33.9681,"lon":151.13564}},{"facility":"Southern Medical Day Care Ctr /ID# 132482","city":"Wollongong","state":"New South Wales","zip":"2500","country":"Australia","geoPoint":{"lat":-34.424,"lon":150.89345}},{"facility":"Flinders Centre for Innovation /ID# 134288","city":"Bedford Park","state":"South Australia","zip":"5042","country":"Australia","geoPoint":{"lat":-35.02204,"lon":138.56815}},{"facility":"Royal Hobart Hospital /ID# 132477","city":"Hobart","state":"Tasmania","zip":"7000","country":"Australia","geoPoint":{"lat":-42.87936,"lon":147.32941}},{"facility":"Qe Ii Hsc /Id# 133408","city":"Halifax","state":"Nova Scotia","zip":"B3H 1V7","country":"Canada","geoPoint":{"lat":44.64269,"lon":-63.57688}},{"facility":"Victoria Hospital /ID# 132161","city":"London","state":"Ontario","zip":"N6A 4L6","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Windsor Regional Hospital /ID# 135989","city":"Windsor","state":"Ontario","zip":"N9C 3Z4","country":"Canada","geoPoint":{"lat":42.30008,"lon":-83.01654}},{"facility":"CSSS Alphonse-Desjardins, CHAU de Levis /ID# 132155","city":"Québec","state":"Quebec","zip":"G6V 3Z1","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Krajska nemocnice Liberec a.s. /ID# 132694","city":"Liberec","zip":"602 00","country":"Czechia","geoPoint":{"lat":50.76711,"lon":15.05619}},{"facility":"Univ Hosp Ostrava-Poruba /ID# 132690","city":"Ostrava","zip":"708 52","country":"Czechia","geoPoint":{"lat":49.83465,"lon":18.28204}},{"facility":"Multiscan s.r.o. /ID# 132689","city":"Pardubice","zip":"532 03","country":"Czechia","geoPoint":{"lat":50.04075,"lon":15.77659}},{"facility":"Vseobecna Fakultni Nemocnice /ID# 135118","city":"Prague","zip":"128 08","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Odense Universitets Hospital /ID# 131912","city":"Odense C","state":"Region Syddanmark","zip":"5000","country":"Denmark","geoPoint":{"lat":55.40841,"lon":10.39538}},{"facility":"Satakunnan Sairaanhoitopiiri /ID# 133632","city":"Pori","zip":"28500","country":"Finland","geoPoint":{"lat":61.48072,"lon":21.78518}},{"facility":"Vaasa Central Hospital /ID# 131930","city":"Vaasa","zip":"65130","country":"Finland","geoPoint":{"lat":63.096,"lon":21.61577}},{"facility":"Charite-Univ. Berlin, Benjamin-Franklin /ID# 131927","city":"Berlin","zip":"12203","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Lungen Clinic Grosshansdorf /ID# 131928","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Univ Klinik Eppendorf Hamburg /ID# 131926","city":"Hamburg","zip":"20246","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Klinik Loewenstein GmbH /ID# 131925","city":"Löwenstein","zip":"74245","country":"Germany","geoPoint":{"lat":49.09558,"lon":9.38}},{"facility":"CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 133441","city":"Miskolc","state":"Borsod-Abauj Zemplen county","zip":"3529","country":"Hungary","geoPoint":{"lat":48.10327,"lon":20.77806}},{"facility":"Orszagos Koranyi Pulmonologiai Intezet /ID# 132738","city":"Budapest XII","state":"Budapest","zip":"1122","country":"Hungary"},{"facility":"Debreceni Egyetem Klinikai Kozpont /ID# 132742","city":"Debrecen","zip":"4032","country":"Hungary","geoPoint":{"lat":47.53167,"lon":21.62444}},{"facility":"Koch Robert Hospital /ID# 133440","city":"Edelény","zip":"3780","country":"Hungary","geoPoint":{"lat":48.3,"lon":20.73333}},{"facility":"Veszprem Megyei Tudogyogyintez /ID# 132739","city":"Farkasgyepű","zip":"8582","country":"Hungary","geoPoint":{"lat":47.2,"lon":17.63333}},{"facility":"Petz Aladar Megyei Oktato Korh /ID# 132741","city":"Győr","zip":"9023","country":"Hungary","geoPoint":{"lat":47.68333,"lon":17.63512}},{"facility":"Matrahaza Gyogyintezet /ID# 132743","city":"Kékesteto","zip":"3233","country":"Hungary"},{"facility":"Assaf Harofeh Medical Center /ID# 132830","city":"Be’er Ya‘aqov","zip":"70300","country":"Israel","geoPoint":{"lat":31.93864,"lon":34.83749}},{"facility":"Shaare Zedek Medical Center /ID# 132834","city":"Jerusalem","zip":"91031","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Meir Medical Center /ID# 132832","city":"Kfar Saba","zip":"4428164","country":"Israel","geoPoint":{"lat":32.175,"lon":34.90694}},{"facility":"Sheba Medical Center /ID# 132833","city":"Ramat Gan","zip":"5239424","country":"Israel","geoPoint":{"lat":32.08227,"lon":34.81065}},{"facility":"Aichi Cancer Center Hospital /ID# 134129","city":"Nagoya","state":"Aichi-ken","zip":"464-8681","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Kurume University Hospital /ID# 134117","city":"Kurume-shi","state":"Fukuoka","zip":"830-0011","country":"Japan"},{"facility":"Hokkaido University Hospital /ID# 134123","city":"Sapporo","state":"Hokkaido","zip":"060-8648","country":"Japan","geoPoint":{"lat":43.06667,"lon":141.35}},{"facility":"Kanagawa Cardiovascular and Respiratory Center /ID# 134127","city":"Yokohama","state":"Kanagawa","zip":"236-0051","country":"Japan","geoPoint":{"lat":35.43333,"lon":139.65}},{"facility":"Sendai Kousei Hospital /ID# 135491","city":"Sendai","state":"Miyagi","zip":"980-0873","country":"Japan","geoPoint":{"lat":38.26667,"lon":140.86667}},{"facility":"Osaka City General Hospital /ID# 134115","city":"Osaka","state":"Osaka","zip":"534-0021","country":"Japan","geoPoint":{"lat":34.69379,"lon":135.50107}},{"facility":"Kindai University Hospital /ID# 134112","city":"Osaka-sayama-shi","state":"Osaka","zip":"589-8511","country":"Japan"},{"facility":"National Cancer Center Hospital /ID# 135129","city":"Chuo-ku","state":"Tokyo","zip":"104-0045","country":"Japan"},{"facility":"The Cancer Institute Hospital Of JFCR /ID# 135492","city":"Koto-ku","state":"Tokyo","zip":"135-8550","country":"Japan"},{"facility":"Yamaguchi - Ube Medical Center /ID# 135284","city":"Ube-shi","state":"Yamaguchi","zip":"755-0241","country":"Japan"},{"facility":"Hiroshima Citizens Hospital /ID# 135130","city":"Hiroshima","zip":"730-8518","country":"Japan","geoPoint":{"lat":34.4,"lon":132.45}},{"facility":"Kishiwada City Hospital /ID# 136548","city":"Kishiwada","zip":"596-8501","country":"Japan","geoPoint":{"lat":34.46667,"lon":135.36667}},{"facility":"Jeroen Bosch Ziekenhuis /ID# 131968","city":"'s-Hertogenbosch","zip":"5223 GZ","country":"Netherlands","geoPoint":{"lat":51.69917,"lon":5.30417}},{"facility":"Vrije Universiteit Medisch Centrum /ID# 131967","city":"Amsterdam","zip":"1081 HV","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Catharina Ziekenhuis /ID# 131966","city":"Eindhoven","zip":"5623 EJ","country":"Netherlands","geoPoint":{"lat":51.44083,"lon":5.47778}},{"facility":"Ziekenhuis St. Jansdal /ID# 131965","city":"Harderwijk","zip":"3844 DG","country":"Netherlands","geoPoint":{"lat":52.34167,"lon":5.62083}},{"facility":"St. Antonius Ziekenhuis /ID# 133635","city":"Nieuwegein","zip":"3435 CM","country":"Netherlands","geoPoint":{"lat":52.02917,"lon":5.08056}},{"facility":"Canterbury District Health Boa /ID# 132469","city":"Christchurch","zip":"8011","country":"New Zealand","geoPoint":{"lat":-43.53333,"lon":172.63333}},{"facility":"Wellington Hospital (Capital and Coast District Health Board) /ID# 132470","city":"Wellington","zip":"6021","country":"New Zealand","geoPoint":{"lat":-41.28664,"lon":174.77557}},{"facility":"Federal State Budgetary Scientific Institution N.N. Blokhin Russian Cancer Resea /ID# 137085","city":"Moscow","state":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Sverdlovsk Regional Oncology Center Dispensary /ID# 132375","city":"Yekaterinburg","state":"Sverdlovsk Oblast","zip":"620043","country":"Russia","geoPoint":{"lat":56.85733,"lon":60.61529}},{"facility":"archangel Clinical Oncology /ID# 132376","city":"Arkhangelsk","zip":"163045","country":"Russia","geoPoint":{"lat":64.5461,"lon":40.55183}},{"facility":"Moscow Regional Onc Dispensary /ID# 132381","city":"Balashikha","zip":"143900","country":"Russia","geoPoint":{"lat":55.79479,"lon":37.94794}},{"facility":"Belgorod Oncology Dispensary /ID# 142638","city":"Belgorod","zip":"308010","country":"Russia","geoPoint":{"lat":50.60343,"lon":36.58091}},{"facility":"Moscow Res Onc Inst Hertsen /ID# 132370","city":"Moscow","zip":"125284","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"State Regional Budgetary Healthcare Institution \" Murmansk Regional Oncology Dis /ID# 137087","city":"Murmansk","zip":"183047","country":"Russia","geoPoint":{"lat":68.96778,"lon":33.09922}},{"facility":"Orenburg Regional Clinical Onc /ID# 132371","city":"Orenburg","zip":"460021","country":"Russia","geoPoint":{"lat":51.76712,"lon":55.09883}},{"facility":"Strategic medical systems LLC /ID# 206383","city":"Saint Petersburg","zip":"192148","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"LLC BioEq Ltd. /ID# 132372","city":"Saint Petersburg","zip":"197342","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"N.N. Petrov Research Inst Onc /ID# 137084","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Ogarev Mordovia State Univ /ID# 132377","city":"Saransk","zip":"430005","country":"Russia","geoPoint":{"lat":54.18485,"lon":45.17166}},{"facility":"GVI Oncology /ID# 133268","city":"Port Elizabeth","state":"Eastern Cape","zip":"6006","country":"South Africa","geoPoint":{"lat":-33.96109,"lon":25.61494}},{"facility":"Dr Albert, Bouwer and Jordaan Incorporated /ID# 131775","city":"Pretoria","state":"Gauteng","zip":"0044","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}},{"facility":"Mary Potter Oncology Centre /ID# 131776","city":"Pretoria","state":"Gauteng","zip":"0181","country":"South Africa","geoPoint":{"lat":-25.74486,"lon":28.18783}},{"facility":"The Oncology Centre /ID# 131773","city":"Durban","state":"KwaZulu-Natal","zip":"4091","country":"South Africa","geoPoint":{"lat":-29.8579,"lon":31.0292}},{"facility":"Netcare Oncology Intervent Ctr /ID# 131777","city":"Cape Town","state":"Western Cape","zip":"7460","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"Cape Town Oncology Trials /ID# 132734","city":"Cape Town","state":"Western Cape","zip":"7570","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"GVI Rondebosch Oncology Centre /ID# 132732","city":"Cape Town","state":"Western Cape","zip":"7700","country":"South Africa","geoPoint":{"lat":-33.92584,"lon":18.42322}},{"facility":"Sandton Oncology Medical Group /ID# 131774","city":"Johannesburg","zip":"2196","country":"South Africa","geoPoint":{"lat":-26.20227,"lon":28.04363}},{"facility":"Dong-A University Hospital /ID# 131609","city":"Busan","state":"Busan Gwang Yeogsi","zip":"49201","country":"South Korea","geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Seoul National Univ Bundang ho /ID# 131610","city":"Seongnam","state":"Gyeonggido","zip":"13620","country":"South Korea","geoPoint":{"lat":35.54127,"lon":127.39683}},{"facility":"Inha University Hospital /ID# 147924","city":"Junggu","state":"Incheon Gwang Yeogsi","zip":"22332","country":"South Korea","geoPoint":{"lat":37.69175,"lon":126.60024}},{"facility":"Chonnam National University Hospital /ID# 131612","city":"Gwangju","state":"Jeonranamdo","zip":"61469","country":"South Korea","geoPoint":{"lat":35.15472,"lon":126.91556}},{"facility":"Samsung Medical Center /ID# 132471","city":"Seoul","state":"Seoul Teugbyeolsi","zip":"06351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Chungbuk National Univ Hosp /ID# 131611","city":"Cheongju-si","zip":"28644","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"Hospital Duran i Reynals /ID# 132879","city":"L'Hospitalet de Llobregat","state":"Barcelona","zip":"08907","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"Hospital Universitario Fundacion Alcorcon /ID# 132909","city":"Alcorcón","zip":"28922","country":"Spain","geoPoint":{"lat":40.34582,"lon":-3.82487}},{"facility":"Hospital General Universitario Alicante /ID# 132881","city":"Alicante","zip":"03010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Hospital Universitario Dexeus - Grupo Quironsalud /ID# 132876","city":"Barcelona","zip":"08028","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario Vall d'Hebron /ID# 132871","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"MD Anderson Madrid /ID# 132905","city":"Madrid","zip":"28033","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario La Paz /ID# 132870","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario HM Sanchinarro /ID# 132869","city":"Madrid","zip":"28050","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Clinico Universitario de Valencia /ID# 132873","city":"Valencia","zip":"46010","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"China Medical University Hosp /ID# 131870","city":"Taichung","state":"Taichung","zip":"40447","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Dalin Tzu Chi General Hospital /ID# 131872","city":"Dalin Township","zip":"622","country":"Taiwan"},{"facility":"Taipei Medical University Hospital /ID# 133817","city":"Taipei","zip":"11031","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Taipei Veterans General Hosp /ID# 131871","city":"Taipei","zip":"11217","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Hacettepe University Medical Faculty /ID# 131913","city":"Ankara","zip":"06100","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Ankara Univ Medical Faculty /ID# 131914","city":"Ankara","zip":"06590","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Uludag University Medical Faculty /ID# 131915","city":"Bursa","zip":"16059","country":"Turkey (Türkiye)","geoPoint":{"lat":40.19559,"lon":29.06013}},{"facility":"Dicle Universitesi Tip /ID# 136570","city":"Diyarbakır","zip":"21200","country":"Turkey (Türkiye)","geoPoint":{"lat":37.91363,"lon":40.21721}},{"facility":"Gaziantep Universitesi Med /ID# 131917","city":"Gaziantep","zip":"27310","country":"Turkey (Türkiye)","geoPoint":{"lat":37.05944,"lon":37.3825}},{"facility":"Dr. Suat Seren Gogus Has /ID# 136568","city":"Izmir","zip":"35110","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"Inonu University /ID# 136569","city":"Malatya","zip":"44280","country":"Turkey (Türkiye)","geoPoint":{"lat":38.35018,"lon":38.31667}},{"facility":"Leicester Royal Infirmary /ID# 133930","city":"Leicester","state":"England","zip":"LE1 5WW","country":"United Kingdom","geoPoint":{"lat":52.6386,"lon":-1.13169}},{"facility":"Cheltenham General Hospital /ID# 131951","city":"Cheltenham","state":"Gloucestershire","zip":"GL53 7AN","country":"United Kingdom","geoPoint":{"lat":51.90006,"lon":-2.07972}},{"facility":"Norfolk and Norwich Univ Hosp /ID# 131953","city":"Norwich","state":"Norfolk","zip":"NR4 7UY","country":"United Kingdom","geoPoint":{"lat":52.62783,"lon":1.29834}},{"facility":"Royal United Hospitals Bath /ID# 132851","city":"Bath","zip":"BA1 3NG","country":"United Kingdom","geoPoint":{"lat":51.3751,"lon":-2.36172}},{"facility":"Belfast City Hospital /ID# 132858","city":"Belfast","zip":"BT9 7AB","country":"United Kingdom","geoPoint":{"lat":54.59682,"lon":-5.92541}},{"facility":"Heart of England NHS Foundation Trust /ID# 132855","city":"Birmingham","zip":"B9 5SS","country":"United Kingdom","geoPoint":{"lat":52.48142,"lon":-1.89983}},{"facility":"Royal Blackburn Hospital /ID# 132853","city":"Blackburn","zip":"BB2 3HH","country":"United Kingdom","geoPoint":{"lat":53.75,"lon":-2.48333}},{"facility":"Colchester General Hospital /ID# 133929","city":"Colchester","zip":"CO4 5JL","country":"United Kingdom","geoPoint":{"lat":51.88921,"lon":0.90421}},{"facility":"Castle Hill Hospital /ID# 135489","city":"Cottingham","zip":"HU16 5JQ","country":"United Kingdom","geoPoint":{"lat":52.50243,"lon":-0.7554}},{"facility":"Scunthorpe General Hospital /ID# 133931","city":"Doncaster","zip":"DN15 7BH","country":"United Kingdom","geoPoint":{"lat":53.52285,"lon":-1.13116}},{"facility":"James Paget University Hosp /ID# 131954","city":"Great Yarmouth","zip":"NR31 6LA","country":"United Kingdom","geoPoint":{"lat":52.60831,"lon":1.73052}},{"facility":"Royal Gwent Hospital /ID# 133935","city":"Gwent","zip":"NP20 2UB","country":"United Kingdom"},{"facility":"Huddersfield Royal Infirmary /ID# 132854","city":"Huddersfield","zip":"HD3 3EA","country":"United Kingdom","geoPoint":{"lat":53.64904,"lon":-1.78416}},{"facility":"Charing Cross Hospital /ID# 131959","city":"London","zip":"W6 8RF","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"The Newcastle Upon Tyne Hospitals NHS Foundation Trust Freeman Hospital /ID# 131661","city":"Newcastle upon Tyne","zip":"NE7 7DN","country":"United Kingdom","geoPoint":{"lat":54.97328,"lon":-1.61396}},{"facility":"York Hospital /ID# 132859","city":"York","zip":"YO31 8HE","country":"United Kingdom","geoPoint":{"lat":53.95763,"lon":-1.08271}}]},"referencesModule":{"references":[{"pmid":"35331641","type":"DERIVED","citation":"Govindan R, Lind M, Insa A, Khan SA, Uskov D, Tafreshi A, Guclu S, Bar J, Kato T, Lee KH, Nakagawa K, Hansen O, Biesma B, Kundu MG, Dunbar M, He L, Ansell P, Sehgal V, Huang X, Glasgow J, Bach BA. Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. Clin Lung Cancer. 2022 May;23(3):214-225. doi: 10.1016/j.cllc.2022.01.005. Epub 2022 Feb 4."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.","infoTypes":["STUDY_PROTOCOL","SAP","CSR","ANALYTIC_CODE"],"timeFrame":"Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.","accessCriteria":"Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.","url":"https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants were randomized in a 1:1 ratio to veliparib in combination with carboplatin and paclitaxel (C/P) or investigator's choice of platinum doublet chemotherapy. Randomization was stratified by smoking status (current versus former), by the investigators' preferred platinum doublet therapy (carboplatin/paclitaxel versus cisplatin/pemetrexed versus carboplatin/pemetrexed), by gender (male versus female) and by Eastern Cooperative Oncology Group (ECOG) performance status (0 versus 1).","recruitmentDetails":"Participants were enrolled at 131 sites in 20 countries (Argentina, Australia, Canada, Czech Republic, Denmark, Finland, Germany, Hungary, Israel, Japan, South Korea, Netherlands, New Zealand, Russian Federation, South Africa, Spain, Taiwan, Turkey, United Kingdom, and United States).","groups":[{"id":"FG000","title":"Investigator's Choice Chemotherapy","description":"Participants received investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:\n\n* Carboplatin at an area under the curve (AUC) of 6 mg/mL\\*min + paclitaxel 200 mg/m²\n* Cisplatin 75 mg/m² + pemetrexed 500 mg/m²\n* Carboplatin AUC 6 or AUC 5 mg/mL\\*min + pemetrexed 500 mg/m²\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."},{"id":"FG001","title":"Veliparib + Carboplatin + Paclitaxel","description":"Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an AUC of 6 mg/mL\\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"297"},{"groupId":"FG001","numSubjects":"298"}]},{"type":"Received Treatment","achievements":[{"groupId":"FG000","numSubjects":"288"},{"groupId":"FG001","numSubjects":"293"}]},{"type":"Received Maintenance Therapy","achievements":[{"groupId":"FG000","numSubjects":"148"},{"groupId":"FG001","numSubjects":"123"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"37"},{"groupId":"FG001","numSubjects":"39"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"260"},{"groupId":"FG001","numSubjects":"259"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"255"},{"groupId":"FG001","numSubjects":"250"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The intention-to-treat (ITT) population included all randomized participants.","groups":[{"id":"BG000","title":"Investigator's Choice Chemotherapy","description":"Participants received investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:\n\n* Carboplatin AUC 6 mg/mL\\*min + paclitaxel 200 mg/m²\n* Cisplatin 75 mg/m² + pemetrexed 500 mg/m²\n* Carboplatin AUC 6 or AUC 5 mg/mL\\*min + pemetrexed 500 mg/m²\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."},{"id":"BG001","title":"Veliparib + Carboplatin + Paclitaxel","description":"Participants received 120 mg veliparib BID on Days -2 to 5 (7 days), carboplatin at an AUC of 6 mg/mL\\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"595"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"595"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"63.1","spread":"8.99"},{"groupId":"BG001","value":"62.7","spread":"9.02"},{"groupId":"BG002","value":"62.9","spread":"9.0"}]}]}]},{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"595"}]}],"categories":[{"title":"< 65 years","measurements":[{"groupId":"BG000","value":"153"},{"groupId":"BG001","value":"163"},{"groupId":"BG002","value":"316"}]},{"title":"≥ 65 years","measurements":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"135"},{"groupId":"BG002","value":"279"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"595"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"182"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"207"},{"groupId":"BG001","value":"206"},{"groupId":"BG002","value":"413"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"595"}]}],"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"48"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"275"},{"groupId":"BG001","value":"272"},{"groupId":"BG002","value":"547"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"595"}]}],"categories":[{"title":"White","measurements":[{"groupId":"BG000","value":"233"},{"groupId":"BG001","value":"229"},{"groupId":"BG002","value":"462"}]},{"title":"Black","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"22"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"110"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"Region","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"595"}]}],"categories":[{"title":"US and Western Europe and Australia and Canada","measurements":[{"groupId":"BG000","value":"177"},{"groupId":"BG001","value":"157"},{"groupId":"BG002","value":"334"}]},{"title":"Eastern Europe/Russia","measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"88"},{"groupId":"BG002","value":"156"}]},{"title":"Japan","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"72"}]},{"title":"Other Asian","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"33"}]}]}]},{"title":"Smoking Status","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"595"}]}],"categories":[{"title":"Current smoker","measurements":[{"groupId":"BG000","value":"153"},{"groupId":"BG001","value":"152"},{"groupId":"BG002","value":"305"}]},{"title":"Past smoker","measurements":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"146"},{"groupId":"BG002","value":"290"}]}]}]},{"title":"Investigators' Preferred Platinum Doublet Therapy","description":"The investigator's preferred choice of platinum doublet therapy, prior to randomization, which was used as a stratification factor. Note that while the investigator's pre-randomization preferred choice for the doublet is summarized, all participants on the veliparib arm received carboplatin and paclitaxel as chemotherapy.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"595"}]}],"categories":[{"title":"Carboplatin/paclitaxel","measurements":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"141"}]},{"title":"Cisplatin/pemetrexed","measurements":[{"groupId":"BG000","value":"95"},{"groupId":"BG001","value":"100"},{"groupId":"BG002","value":"195"}]},{"title":"Carboplatin/pemetrexed","measurements":[{"groupId":"BG000","value":"131"},{"groupId":"BG001","value":"128"},{"groupId":"BG002","value":"259"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"ECOG performance status is used by doctors and researchers to assess how a participant's disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis.\n\n* 0 = Fully Active;\n* 1 = Restricted activity but ambulatory;\n* 2 = Ambulatory but unable to carry out work activities;\n* 3 = Limited Self-Care;\n* 4 = Completely Disabled, No self-care","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"297"},{"groupId":"BG001","value":"298"},{"groupId":"BG002","value":"595"}]}],"categories":[{"title":"Grade 0 (fully active)","measurements":[{"groupId":"BG000","value":"113"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"229"}]},{"title":"Grade 1 (restricted but ambulatory)","measurements":[{"groupId":"BG000","value":"184"},{"groupId":"BG001","value":"182"},{"groupId":"BG002","value":"366"}]}]}]},{"title":"Lung Subtype Panel (LSP) Assay Results","description":"LSP positive: Patients with tumors classified as positive for the gene expression-based lung subtype panel (LSP) biomarker\n\nLSP negative: Patients with tumors classified as negative for the gene expression-based lung subtype panel (LSP) biomarker","populationDescription":"Participants with a tumor tissue sample available with sufficient tumor content for LSP status evaluation, and with an analytically valid LSP result.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"93"},{"groupId":"BG001","value":"114"},{"groupId":"BG002","value":"207"}]}],"categories":[{"title":"LSP positive","measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"80"}]},{"title":"LSP negative","measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"127"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS) in the Lung Subtype Panel Positive Subgroup","description":"Overall survival is defined as the time from the date that the participant was randomized to the date of the participant's death. Overall survival was estimated using Kaplan-Meier methodology. Participants still alive at the data cut-off date were censored at the date they were last known to be alive.","populationDescription":"Participants in the ITT population who were LSP positive (LSP+)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization up to the data cut-off date of 15 July 2019; median follow-up time was 44.5 and 45.3 months in LSP+ participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively.","groups":[{"id":"OG000","title":"Investigator's Choice Chemotherapy","description":"Participants received investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:\n\n* Carboplatin AUC 6 mg/mL\\*min + paclitaxel 200 mg/m²\n* Cisplatin 75 mg/m² + pemetrexed 500 mg/m²\n* Carboplatin AUC 6 or AUC 5 mg/mL\\*min + pemetrexed 500 mg/m²\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."},{"id":"OG001","title":"Veliparib + Carboplatin + Paclitaxel","description":"Participants received 120 mg veliparib BID on Days -2 to 5 (7 days), carboplatin at an AUC of 6 mg/mL\\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","lowerLimit":"5.1","upperLimit":"11.7"},{"groupId":"OG001","value":"11.2","lowerLimit":"7.5","upperLimit":"15.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"A fixed sequence testing procedure was used for analyses of the primary and secondary efficacy endpoints to control for the familywise error rate. If veliparib plus C/P treatment was not statistically significantly better compared to the investigators' choice of standard therapy for the primary efficacy endpoint of OS in LSP+ participants, then statistical significance would not be declared for any of the secondary efficacy endpoints.","pValue":"0.113","pValueComment":"Statistical significance was determined by a two-sided P value ≤ 0.05.","statisticalMethod":"Log Rank","statisticalComment":"Log rank test stratified by ECOG performance status, investigators' preferred platinum therapy, and gender.","paramType":"Hazard Ratio (HR)","paramValue":"0.644","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.396","ciUpperLimit":"1.048","estimateComment":"Hazard ratio obtained using the covariate adjusted Cox Proportional Hazard Model with covariates being ECOG performance status, investigators' preferred platinum therapy, and gender."}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) in the Lung Subtype Panel Positive Subgroup","description":"Progression-free survival is defined as the time from the date of randomization to the date of disease progression (PD) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or death (all causes of mortality), whichever occurred first.\n\nPD: At least a 20% increase in the size of target lesions, taking as reference the smallest size recorded since the treatment started (Baseline or after) with an absolute increase of at least 5 mm, the appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.\n\nPFS was estimated using Kaplan-Meier methodology. Participants who did not have an event of disease progression or had not died on or before the cutoff date were censored at the date of their last disease progression assessment on or before the cut-off date. Any PD and death occurring \\> 26 weeks and \\> 12 weeks after the previous assessment, respectively, were excluded and patients were censored at last assessment before PD or death.","populationDescription":"Participants in the ITT population who were LSP positive","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization up to the data cut-off date of 15 July 2019; the median follow-up time was 44.5 and 45.3 months in LSP+ participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively.","groups":[{"id":"OG000","title":"Investigator's Choice Chemotherapy","description":"Participants received investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:\n\n* Carboplatin AUC 6 mg/mL\\*min + paclitaxel 200 mg/m²\n* Cisplatin 75 mg/m² + pemetrexed 500 mg/m²\n* Carboplatin AUC 6 or AUC 5 mg/mL\\*min + pemetrexed 500 mg/m²\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."},{"id":"OG001","title":"Veliparib + Carboplatin + Paclitaxel","description":"Participants received 120 mg veliparib BID on Days -2 to 5 (7 days), carboplatin at an AUC of 6 mg/mL\\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","lowerLimit":"2.8","upperLimit":"6.2"},{"groupId":"OG001","value":"6.3","lowerLimit":"3.5","upperLimit":"7.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.260","statisticalMethod":"Log Rank","statisticalComment":"Log-rank test stratified by investigator's preferred platinum therapy, gender, and ECOG performance status.","paramType":"Hazard Ratio (HR)","paramValue":"0.647","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.388","ciUpperLimit":"1.080","estimateComment":"The hazard ratio was obtained using the covariate adjusted Cox Proportional Hazard Model with covariates of ECOG performance status, investigators' preferred platinum therapy, and gender."}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) in the Lung Subtype Panel Positive Subgroup","description":"Objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 criteria. Response must have been confirmed at a consecutive assessment 28 days or more after the assessment at which response was first observed.\n\nCR: The disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters, persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, or any new lesions.","populationDescription":"Participants in the ITT population who were LSP positive","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Assessed on Day 1 of Cycles 3 and 5 then every 9 weeks for 1 year or until maintenance therapy was discontinued, then every 12 weeks until radiographic progression or death; median time on follow-up was 5.2 and 6.3 months in each group, respectively.","groups":[{"id":"OG000","title":"Investigator's Choice Chemotherapy","description":"Participants received investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:\n\n* Carboplatin AUC 6 mg/mL\\*min + paclitaxel 200 mg/m²\n* Cisplatin 75 mg/m² + pemetrexed 500 mg/m²\n* Carboplatin AUC 6 or AUC 5 mg/mL\\*min + pemetrexed 500 mg/m²\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."},{"id":"OG001","title":"Veliparib + Carboplatin + Paclitaxel","description":"Participants received 120 mg veliparib BID on Days -2 to 5 (7 days), carboplatin at an AUC of 6 mg/mL\\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","lowerLimit":"16.6","upperLimit":"46.5"},{"groupId":"OG001","value":"22.5","lowerLimit":"10.8","upperLimit":"38.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.455","statisticalMethod":"Regression, Logistic","statisticalComment":"Logistic regression adjusted for the covariates of ECOG performance status, investigators' preferred platinum therapy, and gender.","paramType":"Odds Ratio (OR)","paramValue":"0.66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.23","ciUpperLimit":"1.90","estimateComment":"Odds ratio is from covariate adjusted logistic regression with the covariates being ECOG performance status, investigators' preferred platinum therapy, and gender."}]},{"type":"SECONDARY","title":"Overall Survival in All Participants","description":"Overall survival is defined as the time from the date that the participant was randomized to the date of the participant's death. OS was estimated using Kaplan-Meier methodology. Participants still alive at the data cut-off date were censored at the date they were last known to be alive.","populationDescription":"Participants in the ITT population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization up to the data cut-off date of 15 July 2019; the median OS follow-up time was 45.4 and 44.6 months in all participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively.","groups":[{"id":"OG000","title":"Investigator's Choice Chemotherapy","description":"Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:\n\n* Carboplatin AUC 6 mg/mL\\*min + paclitaxel 200 mg/m²\n* Cisplatin 75 mg/m² + pemetrexed 500 mg/m²\n* Carboplatin AUC 6 or AUC 5 mg/mL\\*min + pemetrexed 500 mg/m²\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."},{"id":"OG001","title":"Veliparib + Carboplatin + Paclitaxel","description":"Participants received 120 mg veliparib BID on Days -2 to 5 (7 days), carboplatin at an AUC of 6 mg/mL\\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"},{"groupId":"OG001","value":"298"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","lowerLimit":"10.0","upperLimit":"13.7"},{"groupId":"OG001","value":"12.1","lowerLimit":"10.4","upperLimit":"14.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.846","statisticalMethod":"Log Rank","statisticalComment":"Log rank test stratified by LSP status, ECOG performance status, investigators' preferred platinum therapy, and gender.","paramType":"Hazard Ratio (HR)","paramValue":"0.986","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.827","ciUpperLimit":"1.176","estimateComment":"The hazard ratio was obtained using the covariate adjusted Cox Proportional Hazard Model with covariates of LSP status, ECOG performance status, investigators' preferred platinum therapy, and gender."}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS) in All Participants","description":"Progression-free survival is defined as the time from the date of randomization to the date of disease progression (PD) per RECIST version 1.1 or death (all causes of mortality), whichever occurred first.\n\nPD: At least a 20% increase in the size of target lesions, taking as reference the smallest size recorded since the treatment started (Baseline or after) with an absolute increase of at least 5 mm, the appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.\n\nPFS was estimated using Kaplan-Meier methodology. Participants who did not have an event of disease progression or had not died on or before the cut-off date were censored at the date of their last disease progression assessment on or before the cut-off date. Any PD and death occurring \\> 26 weeks and \\> 12 weeks after the previous assessment, respectively, were excluded and patients were censored at last assessment before PD or death.","populationDescription":"Participants in the ITT population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization up to the data cut-off date of 15 July 2019; the median follow-up time was 45.4 and 44.6 months in all participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively.","groups":[{"id":"OG000","title":"Investigator's Choice Chemotherapy","description":"Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:\n\n* Carboplatin AUC 6 mg/mL\\*min + paclitaxel 200 mg/m²\n* Cisplatin 75 mg/m² + pemetrexed 500 mg/m²\n* Carboplatin AUC 6 or AUC 5 mg/mL\\*min + pemetrexed 500 mg/m²\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."},{"id":"OG001","title":"Veliparib + Carboplatin + Paclitaxel","description":"Participants received 120 mg veliparib BID on Days -2 to 5 (7 days), carboplatin at an AUC of 6 mg/mL\\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"},{"groupId":"OG001","value":"298"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","lowerLimit":"5.6","upperLimit":"7.2"},{"groupId":"OG001","value":"5.9","lowerLimit":"5.0","upperLimit":"6.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.473","statisticalMethod":"Log Rank","statisticalComment":"Log rank test stratified by LSP status, ECOG performance status, investigators' preferred platinum therapy, and gender.","paramType":"Hazard Ratio (HR)","paramValue":"1.035","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.867","ciUpperLimit":"1.235","estimateComment":"The hazard ratio was obtained using the covariate adjusted Cox Proportional Hazard Model with covariates of LSP status, ECOG performance status, investigators' preferred platinum therapy, and gender."}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) in All Participants","description":"Objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per RECIST version 1.1 criteria. Response must have been confirmed at a consecutive assessment 28 days or more after the assessment at which response was first observed.\n\nCR: The disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters, persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, or any new lesions.","populationDescription":"Participants in the ITT population","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Assessed on Day 1 of Cycles 3 and 5 then every 9 weeks for 1 year or until maintenance therapy was discontinued, then every 12 weeks until radiographic progression or death; median time on follow-up was 6.7 and 5.9 months in each group, respectively.","groups":[{"id":"OG000","title":"Investigator's Choice Chemotherapy","description":"Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:\n\n* Carboplatin AUC 6 mg/mL\\*min + paclitaxel 200 mg/m²\n* Cisplatin 75 mg/m² + pemetrexed 500 mg/m²\n* Carboplatin AUC 6 or AUC 5 mg/mL\\*min + pemetrexed 500 mg/m²\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."},{"id":"OG001","title":"Veliparib + Carboplatin + Paclitaxel","description":"Participants received 120 mg veliparib BID on Days -2 to 5 (7 days), carboplatin at an AUC of 6 mg/mL\\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"297"},{"groupId":"OG001","value":"298"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","lowerLimit":"23.9","upperLimit":"34.5"},{"groupId":"OG001","value":"26.2","lowerLimit":"21.3","upperLimit":"31.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.409","statisticalMethod":"Regression, Logistic","statisticalComment":"Logistic regression adjusted for the covariates of LSP status, ECOG performance status, investigators' preferred platinum therapy, and gender.","paramType":"Odds Ratio (OR)","paramValue":"0.86","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.59","ciUpperLimit":"1.24","estimateComment":"Odds ratio is from covariate adjusted logistic regression with the covariates being LSP status, ECOG performance status, investigators' preferred platinum therapy, and gender."}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"All-cause mortality: From randomization until the end of study; the median follow-up time was 45.4 and 44.6 months in each treatment group, respectively. Adverse events: From first dose of study drug until 30 days after last dose of study drug (veliparib or investigators' choice of standard chemotherapy); median duration of treatment ranged from 86 to 111 days for each treatment.","description":"All-cause mortality is reported for all randomized participants. Adverse events are reported for the as-treated subjects population, which included all participants who received at least 1 dose of study drug (veliparib/investigator's choice of standard chemotherapy).","eventGroups":[{"id":"EG000","title":"Investigator's Choice Chemotherapy","description":"Participants received investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:\n\n* Carboplatin AUC 6 mg/mL\\*min + paclitaxel 200 mg/m²\n* Cisplatin 75 mg/m² + pemetrexed 500 mg/m²\n* Carboplatin AUC 6 or AUC 5 mg/mL\\*min + pemetrexed 500 mg/m²\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.","deathsNumAffected":255,"deathsNumAtRisk":297,"seriousNumAffected":98,"seriousNumAtRisk":288,"otherNumAffected":269,"otherNumAtRisk":288},{"id":"EG001","title":"Veliparib + Carboplatin + Paclitaxel","description":"Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an AUC of 6 mg/mL\\*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.\n\nAfter completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred.","deathsNumAffected":250,"deathsNumAtRisk":298,"seriousNumAffected":121,"seriousNumAtRisk":293,"otherNumAffected":275,"otherNumAtRisk":293}],"seriousEvents":[{"term":"ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":15,"numAtRisk":288},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":293}]},{"term":"FEBRILE NEUTROPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":288},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":293}]},{"term":"LEUKOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"LYMPHADENITIS","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"NEUTROPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":288},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":293}]},{"term":"PANCYTOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"THROMBOCYTOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"ARTERIOSPASM CORONARY","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"ATRIAL FIBRILLATION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":293}]},{"term":"ATRIAL FLUTTER","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"CARDIAC ARREST","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"CARDIAC FAILURE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"CARDIAC FAILURE ACUTE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"CARDIO-RESPIRATORY ARREST","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"CARDIOPULMONARY FAILURE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"LEFT VENTRICULAR FAILURE","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"PERICARDIAL EFFUSION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":293}]},{"term":"PERICARDITIS","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"SUPRAVENTRICULAR TACHYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"ABDOMINAL PAIN","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"APHTHOUS ULCER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"ASCITES","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"COLITIS ISCHAEMIC","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"COLITIS ULCERATIVE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"CONSTIPATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"DIARRHOEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"GASTRITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"HAEMATEMESIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"INTESTINAL OBSTRUCTION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"MESENTERIC VEIN THROMBOSIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"NAUSEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":288},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":293}]},{"term":"OESOPHAGEAL STENOSIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"OESOPHAGITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"RECTAL HAEMORRHAGE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"VOMITING","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":288},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":293}]},{"term":"ASTHENIA","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":293}]},{"term":"CATHETER SITE HAEMORRHAGE","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"CHEST PAIN","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"DISEASE PROGRESSION","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"FATIGUE","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"GENERAL PHYSICAL HEALTH DETERIORATION","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"MALAISE","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"MULTIPLE ORGAN DYSFUNCTION SYNDROME","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"NON-CARDIAC CHEST PAIN","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"PERIPHERAL SWELLING","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"PYREXIA","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"SUDDEN DEATH","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"SYSTEMIC INFLAMMATORY RESPONSE SYNDROME","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"HEPATIC FUNCTION ABNORMAL","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"ANAPHYLACTIC SHOCK","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"DRUG HYPERSENSITIVITY","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":293}]},{"term":"ABDOMINAL ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"APPENDICITIS PERFORATED","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"BACTERAEMIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"BRONCHITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"CELLULITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"CLOSTRIDIUM DIFFICILE COLITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"DEVICE RELATED INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"DIARRHOEA INFECTIOUS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"EMPYEMA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"GASTROENTERITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"HERPES ZOSTER","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"INFLUENZA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"LOWER RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":293}]},{"term":"LUNG INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"LYMPHANGITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"NEUTROPENIC SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"PERITONSILLAR ABSCESS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"PNEUMONIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":288},{"groupId":"EG001","numEvents":26,"numAffected":19,"numAtRisk":293}]},{"term":"PNEUMONIA BACTERIAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"PNEUMONIA PSEUDOMONAL","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"PSEUDOMONAL SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"PULMONARY SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"PYELONEPHRITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"SEPSIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"SEPTIC SHOCK","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"UPPER RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":293}]},{"term":"URINARY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"VASCULAR DEVICE INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"VIRAL UPPER RESPIRATORY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"FALL","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"FEMORAL NECK FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"HEART INJURY","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":293}]},{"term":"HIP FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"LUMBAR VERTEBRAL FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"RADIATION OESOPHAGITIS","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"SPINAL COMPRESSION FRACTURE","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"C-REACTIVE PROTEIN INCREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"DECREASED APPETITE","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"DEHYDRATION","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"HYPOCALCAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"HYPOGLYCAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"HYPONATRAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"TYPE 2 DIABETES MELLITUS","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"ARTHRALGIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"BACK PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":293}]},{"term":"BONE PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"MUSCULOSKELETAL CHEST PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"MUSCULOSKELETAL PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"PAIN IN EXTREMITY","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"CANCER PAIN","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"GASTRIC CANCER","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"MALIGNANT NEOPLASM PROGRESSION","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":288},{"groupId":"EG001","numEvents":19,"numAffected":14,"numAtRisk":293}]},{"term":"MALIGNANT PLEURAL EFFUSION","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"METASTASES TO BONE","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"METASTASES TO CENTRAL NERVOUS SYSTEM","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":293}]},{"term":"METASTASES TO MENINGES","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"PERICARDIAL EFFUSION MALIGNANT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"CEREBRAL INFARCTION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"CEREBRAL ISCHAEMIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":293}]},{"term":"CEREBROVASCULAR ACCIDENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"COGNITIVE DISORDER","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"PERIPHERAL SENSORY NEUROPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"SPINAL CORD COMPRESSION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"CONFUSIONAL STATE","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"DELIRIUM","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"DEPRESSION","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"DISORIENTATION","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"ACUTE KIDNEY INJURY","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"AZOTAEMIA","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"HAEMATURIA","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"RENAL FAILURE","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"RENAL IMPAIRMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"URINARY RETENTION","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"ACUTE RESPIRATORY FAILURE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"DYSPNOEA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":288},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":293}]},{"term":"DYSPNOEA EXERTIONAL","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"HAEMOPTYSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"HYPOXIA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"ORGANISING PNEUMONIA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"PLEURAL EFFUSION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":288},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":293}]},{"term":"PLEURITIC PAIN","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"PNEUMONIA ASPIRATION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"PNEUMOTHORAX","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"PRODUCTIVE COUGH","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"PULMONARY EMBOLISM","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":288},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":293}]},{"term":"PULMONARY HAEMORRHAGE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"RESPIRATORY DISTRESS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"RESPIRATORY FAILURE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"RHINORRHOEA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"SUBCUTANEOUS EMPHYSEMA","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"ANEURYSM","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"AXILLARY VEIN THROMBOSIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":288},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":293}]},{"term":"DEEP VEIN THROMBOSIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"HYPOTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":293}]},{"term":"HYPOVOLAEMIC SHOCK","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"ORTHOSTATIC HYPOTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]},{"term":"VENOUS THROMBOSIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":288},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":293}]}],"otherEvents":[{"term":"ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":197,"numAffected":107,"numAtRisk":288},{"groupId":"EG001","numEvents":212,"numAffected":112,"numAtRisk":293}]},{"term":"LEUKOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":77,"numAffected":40,"numAtRisk":288},{"groupId":"EG001","numEvents":77,"numAffected":43,"numAtRisk":293}]},{"term":"NEUTROPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":175,"numAffected":89,"numAtRisk":288},{"groupId":"EG001","numEvents":210,"numAffected":104,"numAtRisk":293}]},{"term":"THROMBOCYTOPENIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":102,"numAffected":54,"numAtRisk":288},{"groupId":"EG001","numEvents":155,"numAffected":76,"numAtRisk":293}]},{"term":"CONSTIPATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":113,"numAffected":92,"numAtRisk":288},{"groupId":"EG001","numEvents":81,"numAffected":69,"numAtRisk":293}]},{"term":"DIARRHOEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":60,"numAffected":47,"numAtRisk":288},{"groupId":"EG001","numEvents":70,"numAffected":51,"numAtRisk":293}]},{"term":"NAUSEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":202,"numAffected":131,"numAtRisk":288},{"groupId":"EG001","numEvents":121,"numAffected":86,"numAtRisk":293}]},{"term":"STOMATITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":30,"numAtRisk":288},{"groupId":"EG001","numEvents":24,"numAffected":19,"numAtRisk":293}]},{"term":"VOMITING","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":99,"numAffected":73,"numAtRisk":288},{"groupId":"EG001","numEvents":48,"numAffected":39,"numAtRisk":293}]},{"term":"ASTHENIA","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":30,"numAtRisk":288},{"groupId":"EG001","numEvents":58,"numAffected":29,"numAtRisk":293}]},{"term":"FATIGUE","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":117,"numAffected":89,"numAtRisk":288},{"groupId":"EG001","numEvents":108,"numAffected":80,"numAtRisk":293}]},{"term":"OEDEMA PERIPHERAL","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":24,"numAtRisk":288},{"groupId":"EG001","numEvents":16,"numAffected":13,"numAtRisk":293}]},{"term":"PYREXIA","organSystem":"General disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":16,"numAtRisk":288},{"groupId":"EG001","numEvents":17,"numAffected":15,"numAtRisk":293}]},{"term":"WEIGHT DECREASED","organSystem":"Investigations","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":24,"numAtRisk":288},{"groupId":"EG001","numEvents":17,"numAffected":14,"numAtRisk":293}]},{"term":"DECREASED APPETITE","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":109,"numAffected":79,"numAtRisk":288},{"groupId":"EG001","numEvents":79,"numAffected":63,"numAtRisk":293}]},{"term":"HYPERGLYCAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":11,"numAtRisk":288},{"groupId":"EG001","numEvents":24,"numAffected":24,"numAtRisk":293}]},{"term":"HYPOMAGNESAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":16,"numAtRisk":288},{"groupId":"EG001","numEvents":22,"numAffected":21,"numAtRisk":293}]},{"term":"HYPONATRAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":288},{"groupId":"EG001","numEvents":18,"numAffected":16,"numAtRisk":293}]},{"term":"ARTHRALGIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":26,"numAtRisk":288},{"groupId":"EG001","numEvents":45,"numAffected":39,"numAtRisk":293}]},{"term":"BACK PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":22,"numAtRisk":288},{"groupId":"EG001","numEvents":21,"numAffected":17,"numAtRisk":293}]},{"term":"BONE PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":9,"numAtRisk":288},{"groupId":"EG001","numEvents":21,"numAffected":15,"numAtRisk":293}]},{"term":"MYALGIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":17,"numAtRisk":288},{"groupId":"EG001","numEvents":50,"numAffected":38,"numAtRisk":293}]},{"term":"PAIN IN EXTREMITY","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":15,"numAtRisk":288},{"groupId":"EG001","numEvents":17,"numAffected":15,"numAtRisk":293}]},{"term":"DIZZINESS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":22,"numAtRisk":288},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":293}]},{"term":"DYSGEUSIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":29,"numAtRisk":288},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":293}]},{"term":"PERIPHERAL SENSORY NEUROPATHY","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":42,"numAtRisk":288},{"groupId":"EG001","numEvents":195,"numAffected":131,"numAtRisk":293}]},{"term":"INSOMNIA","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":30,"numAtRisk":288},{"groupId":"EG001","numEvents":39,"numAffected":37,"numAtRisk":293}]},{"term":"COUGH","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":29,"numAtRisk":288},{"groupId":"EG001","numEvents":32,"numAffected":27,"numAtRisk":293}]},{"term":"DYSPNOEA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":25,"numAtRisk":288},{"groupId":"EG001","numEvents":46,"numAffected":42,"numAtRisk":293}]},{"term":"HICCUPS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":21,"numAtRisk":288},{"groupId":"EG001","numEvents":27,"numAffected":17,"numAtRisk":293}]},{"term":"OROPHARYNGEAL PAIN","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":15,"numAtRisk":288},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":293}]},{"term":"ALOPECIA","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":40,"numAffected":34,"numAtRisk":288},{"groupId":"EG001","numEvents":160,"numAffected":137,"numAtRisk":293}]},{"term":"RASH","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 21.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":25,"numAtRisk":288},{"groupId":"EG001","numEvents":16,"numAffected":13,"numAtRisk":293}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection."},"pointOfContact":{"title":"Global Medical Services","organization":"AbbVie","email":"abbvieclinicaltrials@abbvie.com","phone":"800-633-9110"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2018-05-09","uploadDate":"2021-02-08T14:57","filename":"Prot_000.pdf","size":3757803},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-11-06","uploadDate":"2021-02-08T14:58","filename":"SAP_001.pdf","size":362215}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["France"]},"conditionBrowseModule":{"meshes":[{"id":"D009362","term":"Neoplasm Metastasis"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D009385","term":"Neoplastic Processes"},{"id":"D009369","term":"Neoplasms"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D017239","term":"Paclitaxel"},{"id":"D016190","term":"Carboplatin"},{"id":"D002945","term":"Cisplatin"},{"id":"C521013","term":"veliparib"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}